The combination of bevacizumab with TRC105 was shown to inhibit VEGF signaling and tip cell formation in vitro and to inhibit tumor growth, metastasis and tumor-associated angiogenesis in a murine breast cancer model [43]. This evidence concerns the gene VEGFA and breast carcinoma.